No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: Better outcome in patients with less proliferative disease

Leukemia

Volumn 17, Issue 9, 2003, Pages 1827-1833

  Hast, R ^a   Hellstrom Lindberg E ^a   Ohm, L ^a   Bjorkholm M ^b   Celsing, F ^b   Dahl, I M ^b   Dybedal, I ^b   Gahrton, G ^b   Lindberg, G ^b   Lerner, R ^b   Linder, O ^b   Lofvenberg E ^b   Nilsson Ehle, H ^b   Paul, C ^b   Samuelsson, J ^b   Tangen, J M ^b   Tidefelt, U ^b   Turesson, I ^b   Wahlin, A ^b   Wallvik, J ^b   Wingquist, I ^b   Oberg G ^b   Bernell, P ^a   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Huddinge University Hospital ^*

Author keywords

Acute myeloid leukemia; Chemotherapy; GM CSF; Myelodysplastic syndromes; Prognostic factors; S LDH

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; CORTICOSTEROID; CYTARABINE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; TIOGUANINE;

ADULT; AGE; AGED; ARTICLE; BONE MARROW CELL; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REGIMEN; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LOGISTIC REGRESSION ANALYSIS; LUNG EDEMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MULTICENTER STUDY; MYCOSIS; MYELODYSPLASTIC SYNDROME; OUTCOMES RESEARCH; PERICARDITIS; PNEUMONIA; PRELEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; SCORING SYSTEM; SEPTICEMIA; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; WEIGHT GAIN;

EID: 0141725590     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403035     Document Type: Article

References (36)

1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
2. de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326-2331.
3. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77: 497-501.
4. Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol 1996; 14: 2486-2494.
5. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997; 90: 2969-2977.
6. Verbeek W, Wormann B, Koch P, Aul C, Hinrichs H, Balleisen L et al. S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Ann Hematol 1997; 74: 205-208.
7. Asano Y, Shibuya T, Okamura S, Yamaga S, Otsuka T, Niho Y. Effect of human recombinant granulocyte/macrophage colony-stimulating factor and native granulocyte colony-stimulating factor on clonogenic leukemic blast cells. Cancer Res 1987; 47: 5647-5648.
8. Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD. The effect of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987; 69: 1771-1776.
9. Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ et al. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1991; 5: 230-238.
10. Bettelheim P, Valent P, Andreff M, Tafuri A, Haimi J, Gorischek C et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid, leukemia. Blood 1991; 77: 700-711.
11. Gianni AM, Gregni M, Siena S, Orazi A, Stern AC, Gandola L et al. Recombinant human granulocyte macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 768-778.
12. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony -stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992; 10: 1266-1277.
13. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia AML Cooperative Study Group. N Engl J Med 1995; 332: 1678-1683.
14. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta F, Hayes FA et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-462.
15. Löwenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997; 90: 2952-2961.
16. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G et al. A randomized double-blind placebo-controlled phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710-4718.
17. Witz F, Sadoun A, Perrin MC, Berthou C, Briere J, Cahn JY et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1998; 91: 2722-2730.
18. Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Delain M et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 2000; 18: 780-787.
19. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332: 1671-1677.
20. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998; 91: 3607-3615.
21. Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 1999; 13: 1214-1220.
22. Hansen PB, Johnsen HE, Jensen L, Gaarsdal E, Simonsen K, Ralfkiaer E. Priming and treatment with molgramostim (rhGM-CSF) in adult high-risk acute myeloid leukemia during induction chemotherapy: a prospective, randomized pilot study. Eur J Haematol 1995; 54: 296-303.
23. Bernasconi C, Alessandrino EP, Bernasconi P, Bonfichi M, Lazzarino M, Canevari A et al. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol 1998; 102: 678-683.
24. Ossenkoppele GJ, van der Holt B, Verhoef GE, Daenen SM, Verdonck LF, Sonneveld P et al. A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group. Leukemia 1999; 13: 1207-1213.
25. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H et al. Randomized phase II study of fludarabine+cytosine arabinoside+idarubicin+/-all-trans retinoic acid+/-granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 93: 2478-2484.
26. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
27. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
28. Öst A, Lagerlöf B, Sundström C, Lindström P, Gyllenhammer H, Engstedt L et al. A study of the reproducibility of the diagnostic criteria for acute leukaemia. Scand J Haematol 1983; 31: 257-266.
29. Bernell P, Kimby E, Hast R. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Leukemia 1994; 8: 1631-1639.
30. Bennett CL, Stinson TJ, Tallman MS, Stadtmauer EA, Marsh RW, Friedenberg W et al. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Ann Oncol 1999; 10: 177-182.
31. Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C+daunorubicin: comparison to patients treated without GM-CSF. Blood 1992; 79: 2246-2255.
32. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001; 158: 879-891.
33. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7: 1071-1080.
34. Åström M, Bodin L, Nilsson I, Tidefelt U. Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden. Br J Cancer 2000; 82: 1387-1392.
35. Wimazal F, Sperr WR, Kundi M, Meidlinger P, Fonatsch C, Jordan JH et al. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leukemia Res 2001; 25: 287-294.
36. Oosterveld M, Muus P, Suciu S, Koller C, Verhoef G, Labar B et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 2002; 16: 1615-1621.